When was ReveraGen founded?

ReveraGen was founded in 2008 and raised its 1st funding round 2 years after it was founded.

Where is ReveraGen located?

ReveraGen is headquartered in Rockville, United States.

How many employees does ReveraGen have?

As of Jul 31, 2026, the latest employee count at ReveraGen is 6.

Is ReveraGen a funded company?

ReveraGen is a funded company, having raised an undisclosed amount across 18 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 16, 2010.

When was the latest funding round of ReveraGen?

ReveraGen's latest funding was a $***** Grant (prize money) round on Sep 27, 2021, with participation from 1 investor. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $1.05B in funding in 2026 to date.

Where does ReveraGen rank among its competitors?

ReveraGen ranks 50th amongst 334 active competitors, of which 50 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Mirum Pharmaceuticals, which secured $68.5M in Jan, 2026.

Who are the top competitors of ReveraGen?

ReveraGen's top competitors include BioMarin Pharmaceutical, Ultragenyx and CRISPR Therapeutics. Among them, Mirum Pharmaceuticals secured the most recent funding round in January, 2026.

ReveraGen - 2026 Company Profile, Team, Funding & Competitors

ReveraGen is a funded company based in Rockville (United States), founded in 2008 by Kanneboyina Nagaraju. It operates as a Developer of steroids for treating Duchenne muscular dystrophy. ReveraGen has raised an undisclosed amount in funding. The company has 334 active competitors, including 50 funded and 78 that have exited. Its top competitors include companies like BioMarin Pharmaceutical, Ultragenyx and CRISPR Therapeutics.

Company Details

ReveraGen is a developer of steroids for treating Duchenne muscular dystrophy. It is a drug development company engaged in the discovery and development of proprietary therapeutic products for neuromuscular diseases such as Duchenne muscular dystrophy (DMD). Its lead product Vamorolone is a steroidal-type anti-inflammatory is being developed for the treatment of DMD.

Website: reveragen.com
Social

Key Metrics

Founded Year

2008

Location

Rockville, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Sep 27, 2021, $*****

Investors

FDA & 11 more

Ranked

50^th among 334 active competitors

Employee Count

6 as on Jul 31, 2026

Similar Companies

BioMarin Pharmaceutical & 129 more

View ReveraGen's full profile

ReveraGen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Reveragen Biopharma, Inc. CIN: 263808415 , United States, Active		-	-	-

ReveraGen has raised funding over 18 rounds. Its first funding round was on Sep 16, 2010. Its latest funding round was a Grant (prize money) round on Sep 27, 2021 for $*****. 1 investor participated in its latest round. ReveraGen has 12 institutional investors.

Here is the list of recent funding rounds of ReveraGen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 27, 2021	3469574	Grant (prize money)	1352799	4133776	6552379	9491148
Sep 15, 2021	3506310	Grant (prize money)	1198270	2770610	8231640	HHS
Nov 17, 2020	1499089	Grant (prize money)	9229381	8815592	9354800	NIH

Access funding benchmarks and valuations. Sign up today!

View details of ReveraGen's funding rounds and investors

The founders of ReveraGen is Kanneboyina Nagaraju. Eric Hoffman is the CEO of ReveraGen.

Here are the details of ReveraGen's key team members:

Kanneboyina Nagaraju: Co-Founder of ReveraGen and founder of 1 other company.
Eric Hoffman: Co-Founder & VP of ReveraGen.
Contact Info: 1 email address

View details of ReveraGen's Founder profiles and Board Members

ReveraGen's employee count trend

ReveraGen has 6 employees as of Jul 26. Here is ReveraGen's employee count trend over the years:

Uncover ReveraGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ReveraGen include BioMarin Pharmaceutical, Ultragenyx and CRISPR Therapeutics. Here is the list of Top 10 competitors of ReveraGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	Temasek, The Grosvenor Funds & 7 others	72/100
2nd	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
3rd	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, New Leaf Venture Partners & 10 others	63/100
4th	AIRNA 2021, Cambridge (United States), Series B	Developer of gene therapies for rare and common diseases	$245M	Forbion, Arch Venture Partners & 9 others	63/100
5th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
6th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Oberland Capital ... & 9 others	61/100
7th	ProQR Therapeutics 2012, Leiden (Netherlands), Public	Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders	$58M	Sofinnova Partners, Gilde Healthcare & 7 others	61/100
8th	Pharvaris 2015, Leiden (Netherlands), Public	Orally deliverable bradykinin B2 antagonists for hereditary angioedema	$164M	Foresite Capital, Life Sciences Partners & 9 others	61/100
9th	American Gene 2008, Rockville (United States), Series B	Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases	$53.1M	Ride wave ventures, Gaingels & 5 others	61/100
10th	Cycle Pharma 2012, Cambridge (United Kingdom), Funding Raised	Small molecule drug reformulation and repurposing for orphan indications	-	robinson-family.ca, Michael A Tory Trust ... & 31 others	59/100
50th	ReveraGen 2008, Rockville (United States), Funding Raised	Developer of steroids for treating Duchenne muscular dystrophy	-	FDA, NINDS & 10 others	41/100